Follow-up evaluation of a phase II prostate cancer vaccine trial

Tjoa, Benjamin A.; Simmons, S.J.; Elgamal, Abdel-Aziz A.; Rogers, M.; Ragde, Haakon; Kenny, Gerald M.; Troychak, M.J.; Boynton, Alton L.; Murphy, Gerald P.

doi:10.1002/(sici)1097-0045(19990701)40:2<125::aid-pros8>3.0.co;2-y

Cited by 125 publications

(35 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, its peptides have been utilized in a vaccine associated with antigen presenting dendritic cells [3]. Favorable responses have been noted in several clinical trials of these vaccines [4, 5, 6, 7]. Although the prostate has the greatest PSMA expression, it is also found in the brain, salivary glands, the small intestine [8], as well as endothelial cells associated with many solid tumors [8].…”

Section: Introductionmentioning

confidence: 99%

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis

Tsui

Rubenstein

Guinan

2005

BioMed Research International

View full text Add to dashboard Cite

Our aim is the identification and correlation of changes in tumor-associated protein expression which results from therapy. LNCaP tumors, excised from nude mice treated either by orchiectomy or with the chemotherapeutic agent paclitaxel, were evaluated for the expression of proteins and receptors associated with growth, differentiation, and angiogenesis using immunohistologic procedures. Compared to untreated control tumors, both treatments reduced the expression of vascular endothelial growth factor (VEGF), prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), androgen receptor (AR), and epidermal growth factor receptor (EGFR). The effect of paclitaxel treatment on AR expression was the most significant (P = .005). Of particular interest was identifying a significant correlation (P < .000801) between PSMA and VEGF expression regardless of treatment modality. These altered expressions suggest that PSMA may also be a marker for angiogenesis and could represent a target for deliverable agents recognizing either prostatic tumors or endothelial development. Cell surface PSMA would then present a unique target for treatment of patients early in their development of prostatic metastases.

show abstract

Section: Introductionmentioning

confidence: 99%

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis

Tsui

Rubenstein

Guinan

2005

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In animal models, T-cell based immunotherapy has already been shown to be feasible, safe and effective in malignant brain tumors [18], melanomas [19] and breast cancer [20]. Promising results with various vaccines in the human system were reported for melanoma [21][22][23], advanced prostate cancer [24] and pancreatic cancer [25,26]. However, therapeutic benefit of active anti-tumor immunotherapy remains to be demonstrated in randomized trials.…”

Section: Discussionmentioning

confidence: 99%

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer

et al. 2007

View full text Add to dashboard Cite

“…The effectiveness of this approach remains controversial, however, as many vaccine trials have not demonstrated a consistent antitumor response or survival advantage despite increased tumor reactive cytotoxic T cells [102–105]. One of the challenges facing therapy directed against single antigens is the ability of a tumor to alter its antigen expression profile, resulting in immune editing.…”

Section: Current Approachesmentioning

confidence: 99%

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment

Jackson

Ruzevick

Phallen

et al. 2011

Clinical and Developmental Immunology

119

109

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Despite intensive treatment, the prognosis for patients with GBM remains grim with a median survival of only 14.6 months. Immunotherapy has emerged as a promising approach for treating many cancers and affords the advantages of cellular-level specificity and the potential to generate durable immune surveillance. The complexity of the tumor microenvironment poses a significant challenge to the development of immunotherapy for GBM, as multiple signaling pathways, cytokines, and cell types are intricately coordinated to generate an immunosuppressive milieu. The development of new immunotherapy approaches frequently uncovers new mechanisms of tumor-mediated immunosuppression. In this review, we discuss many of the current approaches to immunotherapy and focus on the challenges presented by the tumor microenvironment.

show abstract

Follow-up evaluation of a phase II prostate cancer vaccine trial

Cited by 125 publications

References 12 publications

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer

Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment

Contact Info

Product

Resources

About